For a company working with something as messy as live bacteria, mbiomics has managed to raise money with unusual tidiness. The Munich-area biotech closed the final piece of its Series A in April 2026—€12 million that brought the three-year fundraise to €30 million total. Not blockbuster Silicon Valley numbers, but enough to do what founders always promise and rarely deliver: get their lead drug candidate into patients.
The company is targeting something both trendy and treacherous in biotech circles—using the microbiome to treat cancer. Specifically, mbiomics wants to pair carefully designed cocktails of live bacteria with checkpoint inhibitors, the immunotherapy drugs that have already transformed melanoma treatment. Whether microbes can meaningfully boost those results remains an open question. One the company aims to answer with a Phase 1B trial slated for 2027, assuming all goes to plan.
The funding structure itself tells a story about biotech's current climate. Rather than one big splash, mbiomics spread its Series A across three separate closings beginning in March 2023, when MIG Capital led a €13 million first tranche. High-Tech Gründerfonds, Bayern Kapital, and early seed backers joined that initial round. A second closing happened somewhere in between—the company hasn't disclosed how much or exactly when—before MIG Fonds and Bayern Kapital returned for the final €12 million installment.
It's a cadence that reflects either careful capital discipline or the reality of raising money in Europe's more conservative biotech ecosystem. Probably both.
Platform Meets Product
Founded in 2020, mbiomics sits at the intersection of several buzzy scientific trends: microbiome therapeutics, artificial intelligence, advanced imaging. The company's core technology uses high-resolution fluorescence microscopy combined with machine learning to design what it calls "complex, defined microbial consortia." Translation: specific combinations of bacteria, chosen through computational screening rather than the messier process of transplanting entire fecal microbiota.
That distinction matters. The FDA has approved a couple of microbiome products—Rebyota in late 2022, followed by VOWST a few months later in 2023—but both derive from stool samples, which brings inherent variability and manufacturing headaches. Defined consortia, at least in theory, offer cleaner production and smoother regulatory paths. Whether that theory survives contact with clinical reality is what trials are for.
Dr. Johannes B. Woehrstein, the CEO and co-founder whose academic work in multiplexed imaging helped seed the company's platform, framed the moment with the kind of language investors like to hear. "This funding marks our transition from platform building to clinical execution," he said when the latest tranche closed.
Perhaps. The company maintains dual presences in Neuried, just outside Munich, and Boston—a setup that signals ambitions beyond regional markets but also the logistical complexity of straddling two continents.
The Manufacturing Puzzle
Here's where things get interesting, or thorny, depending on your perspective. mbiomics plans to direct much of the fresh capital toward what it calls "IND-enabling pharmacology datasets" and GMP manufacturing development. Both are necessary steps before the FDA will allow human trials, but the manufacturing piece carries special weight for microbiome companies.
Growing complex bacterial communities at scale, consistently, batch after batch? It's proven surprisingly difficult. The field is littered with companies that demonstrated compelling preclinical data only to stumble when trying to manufacture their products reliably. Woehrstein acknowledged the challenge, noting the company aims to show that scalable manufacturing of complex consortia is actually achievable—something the broader microbiome therapeutics sector is still trying to prove.
The lead candidate, MBX-116, is designed as a companion therapy with checkpoint inhibitors for advanced melanoma. The company is eyeing second-line patients initially, those who've already tried frontline treatments. It's a crowded space—Microbiotica and others have presented mechanistic data on similar approaches—but one where even incremental improvements in response rates could matter clinically.
Whether bacteria can genuinely enhance immunotherapy remains contentious. Early preclinical studies have shown intriguing correlations between gut microbiome composition and checkpoint inhibitor response. Turning correlation into causation, and then into a manufacturable product, requires the kind of capital mbiomics just secured. And probably more beyond that, if history is any guide.
The 2027 timeline positions the company to enter trials just as the microbiome oncology field matures—or, less charitably, just as the hype cycle demands proof. Either way, the next chapter moves from the lab to the clinic. That's where theories about bacteria, immunotherapy, and AI-driven design meet the ultimate test: sick patients hoping for better options.
